In the News

About:Energy, a battery technology company, has recently completed a successful seed funding round of £1.5 million. The financing will be allocated towards the rapid commercialisation and development of their software platform, The Voltt, which significantly reduces the cost to design new battery products through virtual prototyping. Shortening battery design timelines will contribute significantly to industry decarbonisation. The funds will also be used to scale their battery lab in London and expand the team. The round also included participation from Theodo CTO Fabrice Bernhard, Coltrane Asset Management Partners' Laura Webster, Mandeep Manku, Nick Banner, among many others.

The spin-out from University College London sells its full portfolio of AI solutions in the successful exit of a commercialised research project and Olympus announce plans to establish Digital Excellence Centres

Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising £6.5 million. By harnessing AI and clinical edge computing, the King’s College London spin-out aims to revolutionise surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties.

OXFORD, England, April 17, 2023 /PRNewswire/ — Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, today announced it has secured a further £13 million (US$16.3 million) to conclude its Series A financing round. Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets.

One of Britain’s biggest banks is getting behind a startup making car ownership less of a hassle, particularly in city centers, where failing to keep up with all manner of taxes and tolls can lead to big fines.

LLoyds Banking Group Plc has put £4 million ($5 million) into Caura, a four-year-old company already backed by Jaguar Land Rover’s venture arm, in its third fintech investment since last year.

Oxford, UK, 19 October 2022 – Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

If you’re a founder working on deep-tech innovations, CDL can connect you with world-class mentors, scientists, and investors to accelerate your startup. The 9-month CDL program runs from October to June and is currently accepting applications for its upcoming program year.

Creative Destruction Lab is launching a specialized Health stream to support cutting-edge digital health, diagnostic and device-based startups developing technologies that collect, use and deploy health data to address emerging needs in human health.

The new Advanced Therapies stream brings together four top institutions, as well as a partnership between CDL and CCRM, a leader in developing and commercializing cell and gene therapies

The Oxford Creative Destruction Lab (CDL) has relaunched its Senior School Girls Programme, following a hiatus owing to the pandemic.

Girls aged 16-18 from Oxfordshire schools have been paired with CDL mentors to observe meetings between the mentors and venture founders at a CDL session.

He was recognized for his contributions as a scholar, mentor, and entrepreneur to enhance Canada's productivity, competitiveness, and prosperity through innovation and entrepreneurship including his initiatives as the founder of the Creative Destruction Lab at the Rotman School and co-founder of Next Canada.

Hosted by ESMT Berlin, Germany’s No. 1 business school, CDL’s newest site is where Europe’s most vibrant startup landscape intersects with a world-class life-science research ecosystem